Full Press Release Details
Ultragenyx Announces Sale of Future European Royalties on Crysvita (burosumab) for $320 Million to Royalty Pharma.
RARE
Ultragenyx Announces Sale of Future European Royalties on Crysvita (burosumab) for $320 Million to Royalty Pharma
Key Takeaway: Ultragenyx Announces Sale of Future European Royalties on Crysvita (burosumab) for $320 Million to Royalty Pharma
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia